About one billion people worldwide are affected by hypertension. The prevalence of essential hypertension increases steadily with age. As the world population ages and preventive strategies in terms of lifestyle changes are so far failing, the prevalence of hypertension is set to increase even further.
Hypertension is a major risk factor for cardiovascular morbidity and mortality. The organs at risk are primarily the heart, the main blood vessels, the brain and the kidneys. The primary goal of any antihypertensive treatment is to prevent cardiovascular events, such as heart attacks or strokes, and finally to reduce cardiovascular mortality. Current evidence suggests that even moderately high blood pressure increases cardiovascular risk and should therefore be treated to achieve blood pressure goals.
Micardis® (telmisartan), MicardisPlus® (telmisartan + hydrochlorothiazide),
Twynsta® (telmisartan + amlodipine)
An international website, www.micardis.com, provides information on Micardis®, MicardisPlus® and Twynsta® and its clinical trial programmes and auxiliary tools such as a CV risk calculator and treatment checklist.
We recognise that the Internet serves a global community. The pharmaceutical industry, however, is subject to country specific regulatory considerations, which affect the information we can provide on our products. In addition the registration status of pharmaceutical products may not be the same in different regions of the world and the approved product labels may also differ according to country specific requirements.
Therefore please check the registration details of this/these product(s) locally in order to get up-to-date information.